577 related articles for article (PubMed ID: 34628534)
21. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Schuler E; Wagner-Drouet EM; Ajib S; Bug G; Crysandt M; Dressler S; Hausmann A; Heidenreich D; Hirschbühl K; Hoepting M; Jost E; Kaivers J; Klein S; Koldehoff M; Kordelas L; Kriege O; Müller LP; Rautenberg C; Schaffrath J; Schmid C; Wolff D; Haas R; Bornhäuser M; Schroeder T; Kobbe G;
Ann Hematol; 2021 Apr; 100(4):959-968. PubMed ID: 33191481
[TBL] [Abstract][Full Text] [Related]
22. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
[TBL] [Abstract][Full Text] [Related]
23. Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.
Carter JL; Su Y; Qiao X; Zhao J; Wang G; Howard M; Edwards H; Bao X; Li J; Hüttemann M; Yang J; Taub JW; Ge Y
Biochem Pharmacol; 2023 Oct; 216():115759. PubMed ID: 37604291
[TBL] [Abstract][Full Text] [Related]
24. Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia.
Chen TT; Lin CC; Lo WJ; Hsieh CY; Lein MY; Lin CH; Lin CY; Bai LY; Chiu CF; Yeh SP
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539418
[TBL] [Abstract][Full Text] [Related]
25. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G
Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355
[TBL] [Abstract][Full Text] [Related]
26. A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML.
Ravindran M; Mozessohn L; Cheung M; Buckstein R; Teichman J
Blood Adv; 2024 Feb; 8(3):629-639. PubMed ID: 38029373
[TBL] [Abstract][Full Text] [Related]
27. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
Venugopal S; Shoukier M; Konopleva M; Dinardo CD; Ravandi F; Short NJ; Andreeff M; Borthakur G; Daver N; Pemmaraju N; Sasaki K; Montalban-Bravo G; Marx KR; Pierce S; Popat UR; Shpall EJ; Kanagal-Shamanna R; Garcia-Manero G; Kantarjian HM; Kadia TM
Cancer; 2021 Oct; 127(19):3541-3551. PubMed ID: 34182597
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Abaza Y; Winer ES; Murthy GSG; Shallis RM; Matthews AH; Badar T; Geramita EM; Kota VK; Swaroop A; Doukas P; Bradshaw D; Helenowski IB; Liu Y; Zhang H; Im A; Litzow MR; Perl AE; Atallah E; Altman JK
Am J Hematol; 2024 Apr; 99(4):606-614. PubMed ID: 38342997
[TBL] [Abstract][Full Text] [Related]
29. Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial.
Amit O; On YB; Perez G; Shargian-Alon L; Yeshurun M; Ram R
Ann Hematol; 2021 Mar; 100(3):817-824. PubMed ID: 33442793
[TBL] [Abstract][Full Text] [Related]
30. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.
Mei M; Aldoss I; Marcucci G; Pullarkat V
Am J Hematol; 2019 Mar; 94(3):358-362. PubMed ID: 30499168
[TBL] [Abstract][Full Text] [Related]
31. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
DiNardo CD; Jonas BA; Pullarkat V; Thirman MJ; Garcia JS; Wei AH; Konopleva M; Döhner H; Letai A; Fenaux P; Koller E; Havelange V; Leber B; Esteve J; Wang J; Pejsa V; Hájek R; Porkka K; Illés Á; Lavie D; Lemoli RM; Yamamoto K; Yoon SS; Jang JH; Yeh SP; Turgut M; Hong WJ; Zhou Y; Potluri J; Pratz KW
N Engl J Med; 2020 Aug; 383(7):617-629. PubMed ID: 32786187
[TBL] [Abstract][Full Text] [Related]
32. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.
Lane AA; Garcia JS; Raulston EG; Garzon JL; Galinsky I; Baxter EW; Leonard R; DeAngelo DJ; Luskin MR; Reilly CR; Stahl M; Stone RM; Vedula RS; Wadleigh MM; Winer ES; Mughal T; Brooks C; Gupta IV; Stevenson KE; Neuberg DS; Ren S; Keating J; Konopleva M; Stein A; Pemmaraju N
Blood Adv; 2024 Feb; 8(3):591-602. PubMed ID: 38052038
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
34. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
Maiti A; DiNardo CD; Qiao W; Kadia TM; Jabbour EJ; Rausch CR; Daver NG; Short NJ; Borthakur G; Pemmaraju N; Yilmaz M; Alvarado Y; Montalbano KS; Wade A; Maduike RE; Guerrero JA; Vaughan K; Bivins CA; Pierce S; Ning J; Ravandi F; Kantarjian HM; Konopleva MY
Cancer; 2021 Nov; 127(22):4213-4220. PubMed ID: 34343352
[TBL] [Abstract][Full Text] [Related]
35. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.
Othman TA; Azenkot T; Moskoff BN; Tenold ME; Jonas BA
Future Oncol; 2021 Aug; 17(23):2989-3005. PubMed ID: 34024158
[TBL] [Abstract][Full Text] [Related]
36. Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.
Gangat N; Tefferi A
Blood Cancer J; 2020 Nov; 10(11):122. PubMed ID: 33230098
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.
Liu B; Guo Y; Deng L; Qiao Y; Jian J
Hematology; 2020 Dec; 25(1):414-423. PubMed ID: 33191860
[TBL] [Abstract][Full Text] [Related]
38. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
Pollyea DA; Pratz K; Letai A; Jonas BA; Wei AH; Pullarkat V; Konopleva M; Thirman MJ; Arellano M; Becker PS; Chyla B; Hong WJ; Jiang Q; Potluri J; DiNardo CD
Am J Hematol; 2021 Feb; 96(2):208-217. PubMed ID: 33119898
[TBL] [Abstract][Full Text] [Related]
39. Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia.
Cui J; Chen X; Li C; Yan Q; Yuan G
Hematology; 2024 Dec; 29(1):2293512. PubMed ID: 38095287
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.
Ustun C; Le-Rademacher J; Wang HL; Othus M; Sun Z; Major B; Zhang MJ; Storrick E; Lafky JM; Chow S; Mrózek K; Attar EC; Nand S; Bloomfield CD; Cripe LD; Tallman MS; Appelbaum F; Larson RA; Marcucci G; Roboz GJ; Uy GL; Stone RM; Jatoi A; Shea TC; de Lima M; Foran JM; Sandmaier BM; Litzow MR; Erba HP; Hurria A; Weisdorf DJ; Artz AS
Leukemia; 2019 Nov; 33(11):2599-2609. PubMed ID: 31073153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
